0000000000014772

AUTHOR

Francesca Napoli

showing 2 related works from this author

The COVID-19 Assessment for Survival at Admission (CASA) Index: A 12 Months Observational Study

2021

Objective: Coronavirus disease 2019 (COVID-19) is a disease with a high rate of progression to critical illness. However, the stratification of patients at risk of mortality is not well defined. In this study, we aimed to define a mortality risk index to allocate patients to the appropriate intensity of care.Methods: This is a 12 months observational longitudinal study designed to develop and validate a pragmatic mortality risk score to stratify COVID-19 patients aged ≥18 years and admitted to hospital between March 2020 and March 2021. Main outcome was in-hospital mortality.Results: 244 patients were included in the study (mortality rate 29.9%). The Covid-19 Assessment for Survival at Admi…

Medicine (General)medicine.medical_specialtyLongitudinal studyFramingham Risk ScoreIndex (economics)Respiratory ratebusiness.industryMortality rateCOVID-19DiseaseGeneral Medicinesystemic scorestratification indexR5-920Internal medicinemedicineRisk of mortalityMedicinemortality riskoutcome researchObservational studybusinessOriginal ResearchFrontiers in Medicine
researchProduct

Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells

2022

Abstract Purpose: Antibodies against the lymphocyte PD-1 (aPD-1) receptor are cornerstone agents for advanced non–small cell lung cancer (NSCLC), based on their ability to restore the exhausted antitumor immune response. Our study reports a novel, lymphocyte-independent, therapeutic activity of aPD-1 against NSCLC, blocking the tumor-intrinsic PD-1 receptors on chemoresistant cells. Experimental Design: PD-1 in NSCLC cells was explored in vitro at baseline, including stem-like pneumospheres, and following treatment with cisplatin both at transcriptional and protein levels. PD-1 signaling and RNA sequencing were assessed. The lymphocyte-independent antitumor activity of aPD-1 was explored in…

chemoresistantCancer ResearchOncologylung cancer cellsAnti–PD-1 Lymphocyte-Independent Activity against NSCLClymphocyte-independent PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cellslymphocyte-independentPD-1 blocking antibody against PD-1+Clinical Cancer Research
researchProduct